

Reply to comment on: Management of Parkinson's disease during pregnancy: Literature review and multidisciplinary input

C Young MD^{1,2} & KJ Peall BMBCh, PhD³

¹Cardiff University School of Medicine, Cardiff University, Cardiff, United Kingdom

²Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

³Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom

Corresponding Authors

Dr. Caitlin Young, Teaching and Learning Centre, Queen Elizabeth University Hospital, Govan Road, Glasgow, G51 4TF, UK. E-mail: caitlin.young@doctors.org.uk

Dr. Kathryn Peall, Neuroscience and Mental Health Research Institute, Cardiff University, Hadyr Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK E-mail: peallkj@cardiff.ac.uk

Word count: 271 (including references)

Key words: Parkinson's disease, pregnancy, treatment

Funding Sources and Conflicts of Interest: The authors declare no conflicts of interest. KJP is funded by an MRC Clinician-Scientist Fellowship (MR/P008593/1)

Financial Disclosures for the previous 12 months: The authors declare no financial disclosures for the previous 12 months.

Dear Editor,

We thank Dr Yen F Tai for his comments on our recently published *Movement Disorders Clinical Practice (MDCP)* article; Management of Parkinson's Disease During Pregnancy: Literature Review and Multidisciplinary Input¹. We welcome this highlighting of an important point not covered in our article. As Dr Tai states, Amantadine is not the most commonly used oral medical therapy in the management of Parkinson's disease. However, in addition to the review highlighted by Dr Tai², studies have shown that oral administration of high-dose Amantadine to rats during gestation to be associated with skeletal abnormalities, including malrotation of hindlimbs and absence of ribs and segments of the spinal column³. Additionally, as cited in Dr Tai's letter, human case reports also detail complications appearing to be associated with intra-uterine exposure to Amantadine⁴, although several others have reported uncomplicated pregnancies⁵. We thank Dr Tai once again for highlighting this point, and caution against the use of Amantadine in pregnancy.

Ethical Compliance Statement

The authors confirm that patient consent was not required for this response letter. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

References

1. Young, C., Phillips, R., Ebenezer, L., Zutt, R. & Peall, K. J. Management of Parkinson's Disease During Pregnancy: Literature Review and Multidisciplinary Input. *Mov. Disord. Clin. Pract.* 2020;7(4):419-430
2. Seier, M. & Hiller, A. Parkinson's disease and pregnancy: An updated review. *Parkinsonism and Related Disorders* 2017;40:11–17
3. Larnar JK, Calhoun FJ, D. A. Effects of amantadine hydro- chloride on cleavage and embryonic development in the rat and rabbit [abstract]. *Toxicol Appl Pharmacol* 1970;17:272
4. Nora, J. J., Nora, A. H. & Way, G. L. Cardiovascular maldevelopment associated with maternal exposure to amantadine *The Lancet* 1975;2:167
5. Levy, M., Pastuszak, A. & Koren, G. Fetal outcome following intrauterine amantadine exposure. *Reprod Toxicol.* 1991;5(1):79-81

Author Roles

Caitlin Young: Manuscript: Writing of the first draft, Kathryn Peall: Manuscript: Review and Critique